Duke University spin out, Affinergy, Inc., is the recipient of five Small Business Innovation Research (SBIR) grants, including a Phase 2 award of nearly $2.1 million funded by the National Institute of General Medical Sciences.
The other four grant awards are for Phase 1 programs that collectively exceed $1 million.
Affinergy produces ‘biolinker’ coatings that adhere to proteins, drugs, cells, and biomaterials used in orthopedic and cardiovascular procedures. This bio-friendly coating works to accelerate the healing and recovery process after surgery.
Affinergy also filled two vice president roles recently to support its growth.
Carmella Moody, Ph.D. joins as vice president of regulatory & quality assurance. Bud Nelson, Ph.D. was promoted from to vice president of intellectual property.
"Carmella and Bud are proven executives who bring invaluable domain expertise to Affinergy in their respective fields," said Peyton Anderson, Affinergy’s chief executive. "They each will play critical leadership roles as we accelerate our programs into the regulatory process while expanding our intellectual property portfolio. Carmella and Bud are highly creative and intelligent professionals who share Affinergy’s passion for building a successful business while helping large numbers of patients. We are honored they have accepted these leadership positions and look forward to harnessing their tremendous talents."
Moody brings over 20 years experience in the life science industry where she held positions of increasing responsibilities in regulatory affairs, quality, and clinical trials with Constella Group, NextGen Pharma, Glaxo Wellcome, Covance Biotechnology Services, and Cato Research. She earned a B.S. from the College of Charleston and earned her M.S. and Ph.D. in Microbiology from NC State University.
Nelson, who completed his law degree at the University of Buffalo, has worked as an intellectual property attorney in biotech and pharmaceutical industries for 13 years and also spent seven years as corporate legal counsel. Prior to Affinergy, he held senior posts at BioCrystal Ltd. and Trimeris, Inc. (NASDAQ: TRMS). Nelson is co-inventor of 10 U.S. Patents and holds a Ph.D. in Immunology and Microbiology.